Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

RYOIX vs. BIB: which is better?

Bottom line

RYOIX vs BIB: the short answer

RYOIX (Biotechnology Fund) and BIB (ProShares Ultra Nasdaq Biotechnology) share a meaningful slice of their top holdings — about 53% by weight.

But BIB is far broader, holding 267 positions to 74 for RYOIX, so beyond the top names it adds exposure RYOIX doesn't have.

BIB is cheaper at 0.95% vs 1.38% — a difference of $43 a year per $10,000 invested.

Over five years, RYOIX returned +4.0% a year vs −1.0% for BIB.

Updated Nov 19, 2026

RYOIX vs BIB side by side

RYOIXBIB
TypeMutual fundETF
Fund familyGuggenheimProShares
CategoryTechnology SectorTechnology Sector
Expense ratio1.38%0.95%
Annual cost per $10k$138$95
10-yr cost on $10k (prospectus)$1,709$1,401
Max front load—None
12b-1 fee0%—
1-yr return+30.7%+59.3%
5-yr return (annualized)+4.0%−1.0%
10-yr return (annualized)+5.9%+1.4%
Best quarter+28.3%+56.2%
Worst quarter−22.5%−42.7%
Net assets (fund)$136.8M$73.7M
Number of holdings74267
Portfolio turnover75%29%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearRYOIXBIBDifference
2025+30.7%+59.3%−28.6%
2024−0.7%−10.0%+9.3%
2023+6.1%−1.3%+7.3%
2022−13.1%−28.6%+15.6%
2021+1.8%−5.9%+7.7%
2020+22.1%+39.7%−17.7%
2019+25.0%+45.5%−20.5%
2018−9.0%−24.4%+15.4%
2017+29.7%+40.8%−11.0%
2016−19.5%−44.2%+24.7%

Source: Fund prospectus bar charts

Holdings overlap

17 of RYOIX's top 25 holdings also appear in BIB's top 25.

Shared top holdings
HoldingRYOIXBIB
Amgen Inc5.05%4.48%
Gilead Sciences Inc4.49%4.66%
Vertex Pharmaceuticals Inc4.32%4.65%
Regeneron Pharmaceuticals Inc2.93%3.21%
Revolution Medicines Inc2.48%1.57%
Alnylam Pharmaceuticals Inc2.36%2.01%
Moderna Inc2.15%0.94%
Biogen Inc2.13%1.44%
Royalty Pharma Plc2.01%1.20%
Illumina Inc1.94%1.25%
Insmed Inc1.79%1.16%
United Therapeutics Corp1.72%1.22%
Guardant Health Inc1.72%0.85%
Roivant Sciences Ltd1.66%1.08%
Incyte Corp1.62%0.97%

Source: SEC Form N-PORT

RYOIX top 10

  1. Abbvie Inc — 8.17%
  2. Amgen Inc — 5.05%
  3. Gilead Sciences Inc — 4.49%
  4. Vertex Pharmaceuticals Inc — 4.32%
  5. Regeneron Pharmaceuticals Inc — 2.93%
  6. Revolution Medicines Inc — 2.48%
  7. Alnylam Pharmaceuticals Inc — 2.36%
  8. Beone Medicines Ltd — 2.17%
  9. Moderna Inc — 2.15%
  10. Biogen Inc — 2.13%

BIB top 10

  1. N/a — 7.35%
  2. ProShares GENIUS Money Market ETF — 6.80%
  3. Gilead Sciences, Inc. — 4.66%
  4. Vertex Pharmaceuticals, Inc. — 4.65%
  5. Amgen, Inc. — 4.48%
  6. N/a — 3.94%
  7. N/a — 3.26%
  8. Regeneron Pharmaceuticals, Inc. — 3.21%
  9. N/a — 2.62%
  10. Alnylam Pharmaceuticals, Inc. — 2.01%

FAQ

What is the difference between RYOIX and BIB?
RYOIX (Biotechnology Fund) and BIB (ProShares Ultra Nasdaq Biotechnology) share a meaningful slice of their top holdings — about 53% by weight. But BIB is far broader, holding 267 positions to 74 for RYOIX, so beyond the top names it adds exposure RYOIX doesn't have.
Which is cheaper, RYOIX or BIB?
BIB has the lower expense ratio (0.95%).
Should I own both RYOIX and BIB?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.